Basal Insulin Therapy in Type 2 Diabetes

References

1. ↵
   American Diabetes Association [homepage on the Internet]. Alexandria (VA): American Diabetes Association; c2002 [cited 2005 Jan 4]. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2002; [about 25 screens]. Available from: http://www.diabetes.org/diabetes-statistics/national-diabetes-fact-sheet.jsp
2. ↵
   American Association of Clinical Endocrinologists. The American Association of Clinical Endocrinologists Medical Guidelines for the Management of Diabetes Mellitus: the AACE system of intensive diabetes self-management—2000 update. Endocr Pract 2000; 6: 43–84.

   OpenUrlPubMed
3. ↵
   Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837–53. Erratum in: Lancet 1999;354:602.

   OpenUrlCrossRefPubMedWeb of Science
4. Deleted in proof.
5. ↵
   Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002; 287: 2563–9.

   OpenUrlCrossRefPubMedWeb of Science
6. ↵
   Leahy JL. Intensive insulin therapy in type 1 diabetes mellitus. In: Leahy JL, Cefalu WT, editors. Insulin therapy. New York: Marcel Dekker; 2002. p. 87–112.
7. ↵
   Del Prato S, Marchetti P, Bonadonna RC. Phasic insulin release and metabolic regulation in type 2 diabetes. Diabetes 2002; 51 Suppl 1: S109–16.

   OpenUrlAbstract/FREE Full Text
8. ↵
   Weir GC, Laybutt DR, Kaneto H, Bonner-Weir S, Sharma A. β-Cell adaptation and decompensation during the progression of diabetes. Diabetes 2001; 50 Suppl 1: S154–9.

   OpenUrlFREE Full Text
9. ↵
   Kaiser N, Leibowitz G, Nesher R. Glucotoxicity and beta-cell failure in type 2 diabetes mellitus. J Pediatr Endocrinol Metab 2003; 16: 5–22.

   OpenUrlPubMedWeb of Science
10. ↵
    DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM. A balanced overview. Diabetes Care 1992; 15: 318–68.

    OpenUrlAbstract/FREE Full Text
11. ↵
    American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2004; 27 Suppl 1: S15–35.
12. ↵
    Home P, Chacra A, Chan J, Emslie-Smith A, Sorensen L, Crombrugge PV; Worldwide Initiative for Diabetes Education (WorldWIDE). Considerations on blood glucose management in Type 2 diabetes mellitus. Diabetes Metab Res Rev 2002; 18: 273–85.

    OpenUrlPubMed
13. ↵
    Feinglos MN, Bethel MA. Oral agent therapy in the treatment of type 2 diabetes. Diabetes Care 1999; 22 Suppl 3: C61–4.
14. ↵
    DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999; 131: 281–303.

    OpenUrlPubMedWeb of Science
15. ↵
    Wright A, Burden AC, Paisey RB, Cull CA, Holman RR; UK Prospective Diabetes Study Group. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002; 25: 330–6. Erratum in: Diabetes Care 2002;25:1268.

    OpenUrlAbstract/FREE Full Text
16. ↵
    Fertig BJ, Simmon DA, Martin DB. Therapy for diabetes. In: National Diabetes Data Group, editor. Diabetes in ameRica. Bethesda (MD): National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 1995. p. 519–40.
17. ↵
    Yki-Jarvinen H, Ryysy L, Nikkila K, Tulokas T, Vanamo R, Heikkila M. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 1999; 130: 389–96.

    OpenUrlCrossRefPubMedWeb of Science
18. ↵
    Goudswaard AN, Stolk RP, Zuithoff P, De Valk HW, Rutten GE. Starting insulin in type 2 diabetes: continue oral hypoglycemic agents? A randomized trial in primary care. J Fam Pract 2004; 53: 393–9.

    OpenUrlPubMedWeb of Science
19. ↵
    Yki-Jarvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care 2000; 23: 1130–6.

    OpenUrlAbstract/FREE Full Text
20. ↵
    Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26: 3080–6.

    OpenUrlAbstract/FREE Full Text
21. ↵
    Feinglos MN, Bethel MA. Treatment of type 2 diabetes mellitus. Med Clin North Am 1998; 82: 757–90.

    OpenUrlCrossRefPubMedWeb of Science
22. ↵
    Galloway JA, Chance RE. Improving insulin therapy: achievements and challenges. Horm Metab Res 1994; 26: 591–8.

    OpenUrlPubMedWeb of Science
23. Brange J, Owens DR, Kang S, Volund A. Monomeric insulins and their experimental and clinical implications. Diabetes Care 1990; 13: 923–54.

    OpenUrlAbstract/FREE Full Text
24. ↵
    Campbell RK, Campbell LK, White JR. Insulin lispro: its role in the treatment of diabetes mellitus. Ann Pharmacother 1996; 30: 1263–71.

    OpenUrlPubMedWeb of Science
25. Kurtzhals P, Schaffer L, Sorensen A, et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000; 49: 999–1005.

    OpenUrlAbstract
26. White JR Jr, Campbell RK, Hirsch I. Insulin analogs: new agents for improving glycemic control. Postgrad Med 1997; 101: 58–5, 70.

    OpenUrl
27. ↵
    Rosskamp RH, Park G. Long-acting insulin analogs. Diabetes Care 1999; 22 Suppl 2: B109–13.
28. ↵
    Campbell RK, White JR, Levien T, Baker D. Insulin glargine. Clin Ther 2001; 23: 1938–57.

    OpenUrlCrossRefPubMed
29. ↵
    Rosenstock J, Schwartz SL, Clark CM Jr, Park GD, Donley DW, Edwards MB. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001; 24: 631–6.

    OpenUrlAbstract/FREE Full Text
30. ↵
    HOE 901/2004 Study Investigators Group. Safety and efficacy of insulin glargine (HOE 901) versus NPH insulin in combination with oral treatment in Type 2 diabetic patients. Diabet Med 2003; 20: 545–551.

    OpenUrlCrossRefPubMed
31. ↵
    Bergenstal RM, Kendall DM, Franz MJ, Rubenstein AH. Management of type 2 diabetes: a systematic approach to meeting the standards of care. II: Oral agents, insulin, and management of complications. In: DeGroot LJ, Jameson JL, editors. Endocrinology. Philadelphia: WB Saunders Co; 2001. p. 821–35.
32. ↵
    Emanuele N, Azad N, Abraira C, et al. Effect of intensive glycemic control on fibrinogen, lipids, and lipoproteins: Veterans Affairs Cooperative Study in Type II Diabetes Mellitus. Arch Intern Med 1998; 158: 2485–90.

    OpenUrlCrossRefPubMedWeb of Science
33. ↵
    Lakka HM, Lakka TA, Tuomilehto J, Sivenius J, Salonen JT. Hyperinsulinemia and the risk of cardiovascular death and acute coronary and cerebrovascular events in men: the Kuopio Ischaemic Heart Disease Risk Factor Study. Arch Intern Med 2000; 160: 1160–8.

    OpenUrlCrossRefPubMedWeb of Science
34. ↵
    Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999; 281: 2005–12.

    OpenUrlCrossRefPubMedWeb of Science